![](https://www.acertx.com/wp-content/uploads/2023/06/NewMission-1024x498.jpg)
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. In the U.S., OLPRUVA™ (sodium phenylbutyrate) is approved for the treatment of urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). Acer is also advancing a pipeline of investigational product candidates for rare and life-threatening diseases, including: OLPRUVA™ (sodium phenylbutyrate) for treatment of various disorders, including Maple Syrup Urine Disease (MSUD); and EDSIVO™ (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
Acer Partners
![https://www.acertx.com/2021/03/22/relief-and-acer-therapeutics-sign-collaboration-and-license-agreement-for-worldwide-development-and-commercialization-of-acer-001-for-the-treatment-of-urea-cycle-disorders-and-maple-syrup-urine-diseas/](https://www.acertx.com/wp-content/uploads/2021/03/LOGO_RELIEF-THERAPEUTICS-300x65.png)
![](https://www.acertx.com/wp-content/uploads/2021/03/Baylor-2-300x144.jpg)
![](https://www.acertx.com/wp-content/uploads/2021/03/assistance-publique-hopitaux-de-paris-ap-hp-logo-vector-2-300x69.jpg)
![](https://www.acertx.com/wp-content/uploads/2021/03/ncats-logo-300x67.png)
![](https://www.acertx.com/wp-content/uploads/2022/12/SchoolMedicine_logo_1c_rgb_h.png)
![](https://www.acertx.com/wp-content/uploads/2023/01/KUMC.png)